首页 | 本学科首页   官方微博 | 高级检索  
     

对我国医药企业自主创新演化机制的分析
引用本文:高院生,吴广谋. 对我国医药企业自主创新演化机制的分析[J]. 价值工程, 2007, 26(8): 48-51
作者姓名:高院生  吴广谋
作者单位:东南大学经济管理学院,南京,211189
摘    要:自主创新是当前商业界和学术界研究比较热的话题。政府相应地制定了一系列的政策和法规来鼓励企业进行自主创新。在这种背景下,我国的医药企业也积极响应国家的政策进行自主创新。然而,医药企业创新在实际操作中的行动方向差异很大。针对这种差异,笔者将医药企业创新划分成新功能创新和新设计创新两种,并且通过对一系列的数据和资料分析后,发现我国的医药企业的创新并非实质上的自主创新即新功能创新,而是新设计创新。文中对产生这种局面的演化机制进行了分析。

关 键 词:自主创新  新功能创新  新设计创新  纳什均衡
文章编号:1006-4311(2007)08-0048-05

To Analyse on Evolved Mechanism of Chinese Medicine Enterprises Active Innovation
Gao Yuansheng,Wu Guanmou. To Analyse on Evolved Mechanism of Chinese Medicine Enterprises Active Innovation[J]. Value Engineering, 2007, 26(8): 48-51
Authors:Gao Yuansheng  Wu Guanmou
Affiliation:Institute of Economics and Management, Southeast University, Nanjing 211189, China
Abstract:Innovation is the hot topic talked by the business and academy community.The government has formulated a series of relevant policies and regulations to encourage enterprises to innovate,in this context,pharmaceutical enterprises in China have responded positively to the national policy of innovation.However,in actual operation,the innovation of pharmaceutical enterprises has many differences in the course of the action.In view of these differences,the author will divided innovation into two kinds: innovation of new functions and innovation of new designs.Through the analysis of a series of data and information,innovation of China's pharmaceutical enterprises has been founded actually not the innovation of new functions,but the innovation of new designs.The text has analysized the mechanism to produce the evolution of this situation.
Keywords:active Innovation  innovation of new functions  innovation of new designs  Nash Equilibrium
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号